Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19. DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Adolescent / Adult / Aged / 80 and over / Antiviral Agents / Azithromycin / Belgium / COVID-19 / Female / Humans / Hydroxychloroquine / Length of Stay / Male / Middle Aged / Multicenter Studies as Topic / Polymerase Chain Reaction / Proof of Concept Study / Randomized Controlled Trials as Topic / SARS-CoV-2 / Standard of Care / Treatment Outcome / Young Adult / COVID-19 Drug Treatment / Antiviral / Macrolide / Randomized controlled trial |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28522665 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/283624 |